Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.
Mahomed S, Paez CA, Huang Y, Seaton KE, Yu C, Gillespie K, Miner MD, Karuna ST, Gamble T, Heptinstall J, Domin E, Tang H, Zhang L, Gao F, Yacovone M, Spiegel HML, Dumond J, Anderson MA, Piwowar-Manning E, Dye BJ, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Kosgei J, Delany-Moretlwe S, Kassim S, Laher F, Chirenje ZM, Musodza Y, Mhlanga F, Mkhize N, Weiner JA, Ackerman ME, McElrath MJ, Pensiero MN, Gama L, Barouch DH, Corey L, Cohen MS, Montefiori DC, Tomaras GD, Siegel M, Kelley CF; HVTN 140/HPTN 101 Study Team.
Mahomed S, et al. Among authors: barouch dh.
Lancet HIV. 2026 May 11:S2352-3018(25)00356-X. doi: 10.1016/S2352-3018(25)00356-X. Online ahead of print.
Lancet HIV. 2026.
PMID: 42114530
Free article.